Armelle Logié

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action <i>in vivo</i> , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Barry R. Davies, Armelle Logié, Jennifer S. McKay et al. · Molecular Cancer Therapeutics · 2007 · 389 citations

Medicine, Oncology, Pharmacology +17

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Tim P. Green, Mike Fennell, Robin Whittaker et al. · Molecular Oncology · 2009 · 256 citations · Full text

Medicine, Oncology, Pharmacology +10

Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans

Armelle Logié, Claire Dunois-Lardé, Christophe Rosty et al. · Human Molecular Genetics · 2005 · 178 citations · Full text

Veterinary Medicine, Genetics, Oncology +17

Increased Levels of Insulin-Like Growth Factor II (IGF-II) and IGF-Binding Protein-2 Are Associated with Malignancy in Sporadic Adrenocortical Tumors¹

Nathalie Boulle, Armelle Logié, Christine Gicquel et al. · The Journal of Clinical Endocrinology & Metabolism · 1998 · 158 citations · Full text

Medicine, Endocrinology, Oncology +11

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft et al. · Oncotarget · 2017 · 158 citations · Full text

Medicine, Oncology, Pharmacology +13